Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEMBRANEBLUE vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Treatment of acquired methemoglobinemia,Diagnostic staining (e.g., parathyroid glands, lymphatic mapping),Off-label: Refractory vasoplegic shock, prevention of ifosfamide neurotoxicity
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Terminal elimination half-life 2.5-3.5 hours in adults; prolonged in hepatic or renal impairment (up to 6-8 hours).
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Reduced by NADPH-dependent methemoglobin reductase to leukomethylene blue; excreted in urine and bile.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal: approximately 60-70% unchanged; biliary/fecal: 20-30% as conjugated metabolites; minor pulmonary excretion.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
0.35-0.45 L/kg, indicating primarily extracellular distribution.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100% (only route); oral bioavailability negligible (<1%) due to extensive first-pass metabolism.
Intravenous: 100%.
No specific dose adjustment recommended; use caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No specific dose adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential for altered metabolism.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
2 mg/kg intravenously once, not to exceed 100 mg total dose; repeat dosing not typically recommended.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
No specific dose adjustment required; monitor for renal function and fluid overload due to age-related physiological changes.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
Serotonin syndrome with concurrent serotonergic drugs (especially SSRIs, SNRIs, MAOIs); discontinue serotonergic agents prior to use; do not use in patients taking serotonergic drugs.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Risk of serotonin syndrome when used with serotonergic agents; may cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; may cause interferences with pulse oximetry readings; monitor methemoglobin levels; may cause fetal harm.
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Known hypersensitivity to methylene blue; concurrent use with serotonergic drugs (SSRIs, SNRIs, MAOIs); severe G6PD deficiency.
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No known food interactions. Avoid alcohol consumption for 24 hours post-administration due to potential increased sedative effects.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Breastfeeding safety not established. M/P ratio unknown. Use caution during lactation due to potential for excretion.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No dose adjustment required based on pharmacokinetic changes during pregnancy.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
MEMBRANEBLUE (methylene blue) 1% solution is used intravenously for methemoglobinemia and as an optical imaging agent. Monitor for serotonergic toxicity if combined with SSRIs/SNRIs due to MAO inhibition. Do not exceed 7 mg/kg total dose to avoid severe adverse effects. Use with caution in G6PD deficiency due to risk of hemolytic anemia.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This medication may cause your urine, stool, or skin to turn blue-green, which is harmless and temporary.,Report any severe headache, chest pain, or difficulty breathing immediately.,Avoid taking medications for depression, anxiety, or migraine (SSRIs, SNRIs, MAOIs) within 24 hours of receiving MEMBRANEBLUE unless directed by your doctor.,If you have a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, inform your healthcare provider before treatment.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEMBRANEBLUE vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
MEMBRANEBLUE is a Ophthalmic Dye that works by Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEMBRANEBLUE and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEMBRANEBLUE is: 2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEMBRANEBLUE and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEMBRANEBLUE is classified as Category C. Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.